Bruton's tyrosine kinase inhibitors

Abstract

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

1 . A pharmaceutical salt of a compound having the formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 X 1  is —O—, —CR 5 R 6 —, or —NR 7 —; 
 X 2  is ═CR 8 — or ═N—; 
 p is 0-5; 
 y is 0, 1, or 2; 
 z is 0, 1, or 2, wherein z is 0 or 1 when y is 2, and z is 1 or 2 when y is 0; 
 each R 1  is independently halogen, —NO 2 , —CN, —OR, —SR, —N(R) 2 , —C(O)R, —CO 2 R, —C(O)C(O)R, —C(O)CH 2 C(O)R, —S(O)R, —S(O) 2 R, —C(O)N(R) 2 , —SO 2 N(R) 2 , —OC(O)R, —N(R)C(O)R, —N(R)N(R) 2 , —N(R)C(═NR)N(R) 2 , —C(═NR)N(R) 2 , —C═NOR, —N(R)C(O)N(R) 2 , —N(R)SO 2 N(R) 2 , —N(R)SO 2 R, —OC(O)N(R) 2 , or an optionally substituted group selected from C 1-12  aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, ad sulfur, or:
 two R 1  groups on adjacent carbon atoms are taken together with their intervening atoms to form an optionally substituted ring selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, ad sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, ad sulfur, or: 
 two R 1  groups on non-adjacent carbon atoms are taken together with their intervening atoms to form an optionally substituted bridge of a bridged bicyclic group, wherein the bridge is a C 1-3  hydrocarbon chain wherein one methylene unit is optionally replaced by —NR—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—S—, or —S—, or: 
 two R 1  groups on the same carbon atom are taken together with their intervening atoms to form an optionally substituted spiro fused ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 
 
 each R is independently hydrogen or an optionally substituted group selected from C 1-6  aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
 two R groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted 3-7 membered saturated, partially unsaturated, or heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 
 
 each of R 2 , R 3 , R 5 , R 6 , and R 8  is independently R, halogen, —NO 2 , —CN, —OR, —SR, —N(R) 2 , —C(O)R, —CO 2 R, —C(O)C(O)R, —C(O)CH 2 C(O)R, —S(O)R, —S(O) 2 R, —C(O)N(R) 2 , —SO 2 N(R) 2 , —OC(O)R, —N(R)C(O)R, —N(R)N(R) 2 , —N(R)C(═NR)N(R) 2 , —C(═NR)N(R) 2 , —C═NOR, —N(R)C(O)N(R) 2 , —N(R)SO 2 N(R) 2 , —N(R)SO 2 R, or —OC(O)N(R) 2 ; or:
 R 3  and R 4  are optionally taken together with their intervening atoms to form an optionally substituted ring selected from pyrrole, pyrazole, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 
 
 each of R and R 7  is independently R, —CN, —C(O)R, —CO 2 R, —C(O)C(O)R, —C(O)CH 2 C(O)R, —C(O)N(R) 2 , —S(O)R, —S(O) 2 R, or —S(O) 2 N(R) 2 ; 
 Ring A is 
 
       
         
           
           
               
               
           
         
         
           and is optionally substituted, 
           wherein T is an optionally substituted, bivalent C 1-5  saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of T are optionally and independently replaced by —C(R) 2 —, —NR—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO 2 —, —SO 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, —C(═S)—, —C(═NR)—, —N═N—, or —C(═N 2 )—; 
         
         Ring A 2  is an optionally substituted ring selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 
         L is a covalent bond or an optionally substituted, bivalent C 1-7  saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L are independently replaced by -Cy-, —CR 2 —, —NR—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO 2 —, —SO 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, —C(═S)—, —C(═NR)—, —N═N—, or —C(═N 2 )—, wherein at least one methylene unit of L is replaced by —N(R)—; and 
         each Cy is independently an optionally substituted bivalent ring selected from phenylene, a 3-7 membered saturated or partially unsaturated carbocyclylene, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 
       
     
     
         2 .- 4 . (canceled) 
     
     
         5 . The pharmaceutical salt of  claim 1 , wherein L is —NH—C(O)—NH—, —NH—C(O)—, —NH—, or —NHSO 2 —. 
     
     
         6 . The pharmaceutical salt of  claim 5 , wherein L is —NH—C(O)—NH— or —NH—. 
     
     
         7 . The pharmaceutical salt of  claim 1 , wherein L is: 
       
         
           
           
               
               
           
         
       
       wherein s and t are independently 0, 1, or 2, and the sum of s and t is 0-4. 
     
     
         8 .- 15 . (canceled) 
     
     
         16 . The pharmaceutical salt of  claim 1 , wherein the compound is of formula I-a-i, or I-a-ii: 
       
         
           
           
               
               
           
         
       
     
     
         17 . The pharmaceutical salt of  claim 1 , wherein the compound is of formula I-b-i, or I-b-ii: 
       
         
           
           
               
               
           
         
       
     
     
         18 .- 20 . (canceled) 
     
     
         21 . The pharmaceutical salt of  claim 1 , wherein R 4  is hydrogen. 
     
     
         22 . (canceled) 
     
     
         23 . The pharmaceutical salt of  claim 1 , wherein R 1  is halogen, —CN, or optionally substituted C 1-6  aliphatic. 
     
     
         24 .- 32 . (canceled) 
     
     
         33 . The pharmaceutical salt of  claim 1 , wherein X 1  is —CR 5 R 6 —. 
     
     
         34 .- 50 . (canceled) 
     
     
         51 . The pharmaceutical salt of  claim 1 , wherein Ring A 1  is: 
       
         
           
           
               
               
           
         
       
       and is optionally substituted, wherein q is 0-4. 
     
     
         52 . (canceled) 
     
     
         53 . The pharmaceutical salt of  claim 51 , wherein q is 2. 
     
     
         54 . (canceled) 
     
     
         55 . The pharmaceutical salt of  claim 51 , wherein the compound is of formula XI: 
       
         
           
           
               
               
           
         
       
     
     
         56 . The pharmaceutical salt of  claim 1 , wherein Ring A 2  is an optionally substituted ring selected from phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 
     
     
         57 . (canceled) 
     
     
         58 . The pharmaceutical salt of  claim 56 , wherein Ring A 2  is optionally substituted phenyl. 
     
     
         59 . The pharmaceutical salt of  claim 58 , wherein substituents on Ring A 2  are selected from R, halogen, —CN, —CF 3 , —OH, —OR, —NH 2 , —N(R) 2 , —COOH, —SR, —S(O)R, —S(O) 2 R, —S(O)N(R) 2 , and —S(O) 2 N(R) 2 . 
     
     
         60 . The pharmaceutical salt of  claim 59 , wherein Ring A 2  is of the formula: 
       
         
           
           
               
               
           
         
       
       wherein R h  is F, Cl, Br, or I. 
     
     
         61 . The pharmaceutical salt of  claim 58 , wherein the ortho carbons on Ring A 2  are independently R, halogen, —CN, —CF 3 , —OH, —OR, —NH 2 , —N(R) 2 , or —COOH. 
     
     
         62 .- 63 . (canceled) 
     
     
         64 . The pharmaceutical salt of  claim 61 , wherein Ring A 2  is selected from: 
       
         
           
           
               
               
           
         
       
     
     
         65 . The pharmaceutical salt of  claim 64 , wherein Ring A 2  is: 
       
         
           
           
               
               
           
         
       
     
     
         66 . The pharmaceutical salt of  claim 1 , wherein the compound is a compound as shown in Table 1. 
     
     
         67 .- 74 . (canceled)